Sean Grant is CFO at Vera Therapeutics, Inc. (VERA). They have made 6 open-market trades across 1 company since 2022, most recently 2026-02-23.
CIK 0001872792
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $351K since 2022, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VERA | 114,181 | $3.2M |
Shares reported on the most recent Form 4, priced at the 2026-02-25 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VERA | SELL | 2026-02-23 | 2026-02-25 | $41.98 | $208K | -5.5% | -5.8% | -16.8% |
| VERA | SELL | 2024-04-03 | 2024-04-05 | $39.59 | $9.2M | +9.2% | +24.3% | -2.7% |
| VERA | BUY | 2023-06-23 | 2023-06-23 | $16.60 | $83K | -12.4% | -10.3% | -14.1% |
| VERA | BUY | 2023-02-06 | 2023-02-17 | $7.00 | $100K | -14.2% | -11.4% | -12.3% |
| VERA | BUY | 2022-06-15 | 2022-06-16 | $13.60 | $68K | -1.1% | +16.6% | +56.5% |
| VERA | BUY | 2022-02-06 | 2023-02-08 | $7.00 | $100K | +4.0% | -4.7% | -1.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.